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ical trials registries, and EMA reports. We extracted data for depression severity
(mean differences or related statistics) on the primary comparisons of 1) agomela-
tine 25 mg/day versus placebo, and 2) agomelatine 25 mg/day versus any SSRI. We
calculated Hedges’ g effect size for each trial and combined them by the inverse
variance method assuming a random effects model. Two meta-analyses were con-
ducted: one with the results of published and unpublished trials and the other only
with results of published trials. RESULTS: Ten trials (5 unpublished) gave data on
the efficacy of agomelatine versus placebo. Overall, the results were homogeneous
(I2  9.2%), and showed agomelatine was better than placebo for reducing the
severity of depression at 8 weeks (g  -0.18; 95% CI  -0.25 to -0.10; p 0.0001).
However when the analysis was restricted to published trials the effect size was
45% overestimated (g  -0.26; 95% CI  -0.36 to-0.15; p  0.0001; I2  3.4%). 7 trials
(4 unpublished) gave data on the comparison of agomelatine versus any SSRI.
There was no difference in efficacy with all trials combined (g 0.01; 95% CI -0.16
to 0.18; p 0.87), but agomelatine significantly outperformed SSRIs in the subset of
published trials (g  -0.17; 95% CI  -0.29 to -0.05; p  0.0052). CONCLUSIONS:
When combining all available data agomelatine presents a small to moderate effi-
cacy as antidepressant with similar effect sizes to those reported for SSRIs. Previ-
ous reports pointing to better results of agomelatine as compared with SSRIs are
the result of selective publication bias.
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OBJECTIVES: This study aimed to describe the functional level of patients treated
with olanzapine long-acting injection (OLZ-LAI) during maintenance treatment of
schizophrenia for up to 24 weeks. A secondary objective was to compare OLZ-LAI
with oral olanzapine on these functional measures. METHODS: We present a sec-
ondary analysis of a multicenter, randomized, double-blind, study comparing the
safety and efficacy of OLZ-LAI (405mg/4weeks, 300mg/2weeks, 150 mgs/2weeks,
active depot groups) with oral olanzapine and OLZ-LAI 45mg/4weeks (very low
dose/pseudo-placebo group) for maintenance treatment of clinically stable pa-
tients with schizophrenia (n1064). Heinrichs and Carpenter’s Quality of Life Scale
(QLS) mean total scores were calculated for each of the three active OLZ-LAI treat-
ment groups and for their pooled group. Patients’ functional status was also clas-
sified - at baseline and endpoint, per QLS - as “good,” “moderate” or “poor” using a
recent data-driven approach to defining levels of functioning in schizophrenia.
RESULTS: Over the 24-week treatment period, the OLZ-LAI-treated patients im-
proved their level of functioning - per QLS total score - from a mean (SD) of 66.4
(18.9) to 72.0(19.1) (p0.001). At baseline, 16.8% of the OLZ-LAI-treated patients
were identified as having a “good” level of functioning, which increased to 27.5%
following up to 24 weeks of therapy (p0.001). There was a decrease both in the
proportion of patients with a “moderate” level of functioning (from 66.8 to 61.8%;
p0.002) and patients with a “poor” level of functioning (from 16.3% to 10.7%;
p0.06). Results were not significantly different between oral olanzapine and the
three OLZ-LAI active dosing groups or the pooled OLZ-LAI treatment group.
CONCLUSIONS: In this 24-week study, clinically stable patients treated with OLZ-
LAI maintained their favorable baseline level of functioning or further improved it
over time. Results did not significantly differ between OLZ-LAI and oral olanzapine.
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OBJECTIVES: Data on attaining and maintaining symptom remission associated
with specific antipsychotic medications are rare and variant. The aim of this study
is to examine remission rates and their variation by antipsychotic medication in
chronic schizophrenia in the National Institute of Mental Health Clinical Antipsy-
chotic Trials of Intervention Effectiveness (CATIE) give it has an 18-month duration
and representative antipsychotic medications. METHODS: Symptom remission
was examined using the Remission in Schizophrenia Working Group remission
criteria of attaining and maintaining for 6 months with mild ratings on 8 specific
Positive and Negative Syndrome Scale (PANSS) items. Remission rates were as-
sessed (a) up to 18 months across CATIE’s switching phases (n1332); and (b) in
phase 1 (that involved double-blind randomization to one of five antipsychotic
medications) to compare antipsychotic medication differences in attaining and
maintaining remission among patients not in remission at baseline (n941).
RESULTS: A total of 15.7% of patients were in symptomatic remission at baseline.
Across the switching phases of CATIE only 11% attained and then maintained at
least 6 months of symptomatic remission, and 55.5% (n623) experienced no
symptom remission at any visit. In phase 1, attaining and maintaining remission
for 6 months was highest for the olanzapine (13.3%) medication group followed by
quetiapine (8.9%), ziprasidone (6.6%), perphenazine (6.2%), and risperidone (6.2%)
groups. CONCLUSIONS: As currently defined, remission appears to be a very diffi-
cult therapeutic target to attain and maintain in chronic schizophrenia and may
differ by antipsychotic medication. Pragmatically, remission gradients may be ef-
fectively studied by applying modified duration and symptom criteria.
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OBJECTIVES:Despite marked heterogeneity among patients with schizophrenia in
their level of functioning, little is known what “good” “moderate” or “poor” levels of
functioning look like on various functional measures. This study used an empirical
approach to identify and then validate these functional definitions.METHODS:We
used baseline data of a multicenter, effectiveness study comparing antipsychotics
in the treatment of outpatients with schizophrenia (n524; NCT00320489), as this
study included several functional measures. A cluster analysis used the Heinrich’s
Carpenter Quality of Life Scale (QLS), the 12-item Short Form Health Survey (SF-12)
mental composite score, and a previously studied productivity measure, to classify
patients into functional groups. A three cluster solution was chosen to maximize
simplicity, explanatory power and separation among the groups. Clusters were
validated using two other functional measures and two previously published def-
initions of functional levels: an empirical definition that incorporated functioning
and symptom severity, and another, using theoretically-driven definitions. Classi-
fication and regression tree (CART) analysis was used to establish the criteria for
classifying functioning as “good” “moderate” or “poor” with the QLS. RESULTS: The
three clusters consistently differentiated patients on the QLS, SF-12 and produc-
tivity measures, reflecting “good” “moderate” and “poor” functional levels. The
clusters similarly differed on other functional measures (the Schizophrenia Out-
comes Functioning Interview [SOFI] and the Euro-QOL-5D scale), and were concor-
dant with two previously published functional classifications. The CART analysis
identified “good” functioning as QLS total score 84.5, whereas “moderate” and
“poor” functioning were separated by a cut-off score of 15.5 on the QLS intrapsychic
foundation domain. Sensitivity ranged from 86% to 93% and specificity from 89% to
99%. CONCLUSIONS: The substantial heterogeneity among schizophrenia patients
in their level of functioning can be reliably classified in an empirical manner, using
specific cut-off scores on commonly used functional measures. Findings have util-
ity for schizophrenia research.
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OBJECTIVES: Treatment continuity plays a major role in achieving favorable out-
comes in patients suffering from schizophrenia. Long-acting injectable risperidone
(RLAI) has shown its beneficial effects compared to oral antipsychotics (oAP) in
randomized controlled trials, but observational data reflecting routine clinical
practice are sparse. Objective is to evaluate the clinical effectiveness of RLAI com-
pared to oAP in clinical practice. METHODS: A total of 746 patients with schizo-
phrenia newly initiated from oral antipsychotic treatment to either an atypical oAP
(n268) or RLAI (n478) were enrolled in this prospective, longitudinal 24-month
open-label observational study. Primary efficacy measure was time to discontinu-
ation of medication using Kaplan-Meier and multivariate Cox proportional hazards
regression, adjusting for patient demographics, disease severity and treatment
history. RESULTS: At baseline, patients treated with RLAI were more likely to be
male, non-compliant, substance abuser, and had significantly higher levels of psy-
chotic symptoms and disease severity, poorer psychosocial functioning (GAF, days
unable to work), and poorer cognitive function, compared to patients treated with
oral antipsychotics. 107 patients were identified as having a history of poor adher-
ence (RLAI: n84; oral: n23) with previous antipsychotic treatment. Time to treat-
ment discontinuation was numerically but not significantly longer for patients
treated with RLAI compared to patients treated with atypical oAP. Among the
subset of patients with history of poor adherence this difference was significant
(unadjusted hazard ratio0.42, p.014; adjusted hazard ratio0,35; p0,0098).
Symptom improvement was significantly better for patients on RLAI as compared
to oAP on the Positive and Negative Syndrome Scale (PANSS) total score (p.029),
positive (p.004) and negative (p.023) subscores, respectively. CONCLUSIONS: In
routine clinical practice, RLAI appears to be used more frequently in patients with
more severe schizophrenia, substance abuse and poor adherence. The benefits of
RLAI treatment compared to oAP seem to be most pronounced in a subset of pa-
tients with poor adherence.
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OBJECTIVES: Asenapine is a novel antipsychotic indicated for the treatment of
moderate to severe manic episodes associated with bipolar I disorder. The clinical
programme included one 12-week trial versus olanzapine in monotherapy and one
12-week adjunct therapy trial versus placebo. While no head-to-head data were
available to compare asenapine with all atypical antipsychotics, the objective of
this project was to provide comparative efficacy data of asenapine versus olanzap-
ine, quetiapine and aripiprazole in both monotherapy and adjunct therapy using
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